"uuid:ID","description","instanceType","label","name","id","rationale"
"a32f4ba0-85eb-4d84-881b-8696af4c5863","The main design for the study","StudyDesign","","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
